- Home
- NCMI vs NMRA Comparison
NCMI vs NMRA Comparison
Compare NCMI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCMI | NMRA |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 424.4M |
| IPO Year | 2007 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NCMI | NMRA |
|---|---|---|
| Price | $3.82 | $2.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $6.63 | ★ $8.00 |
| AVG Volume (30 Days) | 269.2K | ★ 2.4M |
| Earning Date | 03-05-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,300,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $11.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.68 | $0.61 |
| 52 Week High | $7.25 | $3.25 |
Technical Indicators
Market Signals| Indicator | NCMI | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 53.06 |
| Support Level | $3.72 | $1.84 |
| Resistance Level | $3.96 | $2.20 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 30.00 | 56.54 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.